MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas

Jayasree S. Nair(Memorial Sloan Kettering Cancer Center), Gary K. Schwartz(Cornell University)

Oncotarget

February 12, 2016

10.18632/oncotarget.7335

Cited by 34

Related Papers

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

|Journal of Clinical Oncology|2009|573

Aurora Kinases: New Targets for Cancer Therapy

|Clinical Cancer Research|2006|274

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

|Oncotarget|2015|112

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

|PLoS ONE|2012|77

90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G2/M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1

|Molecular Pharmacology|2008|44